Alirocumab vs usual lipid‐lowering care as add‐on to statin therapy in individuals with type 2 diabetes and mixed dyslipidaemia: The ODYSSEY DM‐DYSLIPIDEMIA randomized trial

AIM: To compare alirocumab, a proprotein convertase subtilisin‐kexin type 9 inhibitor, with usual care (UC) in individuals with type 2 diabetes (T2DM) and mixed dyslipidaemia not optimally managed by maximally tolerated statins in the ODYSSEY DM‐DYSLIPIDEMIA trial (NCT02642159). MATERIALS AND METHOD...

Descripción completa

Detalles Bibliográficos
Autores principales: Ray, Kausik K., Leiter, Lawrence A., Müller‐Wieland, Dirk, Cariou, Bertrand, Colhoun, Helen M., Henry, Robert R., Tinahones, Francisco J., Bujas‐Bobanovic, Maja, Domenger, Catherine, Letierce, Alexia, Samuel, Rita, Del Prato, Stefano
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2018
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5969299/
https://www.ncbi.nlm.nih.gov/pubmed/29436756
http://dx.doi.org/10.1111/dom.13257

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5969299/
https://www.ncbi.nlm.nih.gov/pubmed/29436756
http://dx.doi.org/10.1111/dom.13257

Ejemplares similares